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Keypoints:  
• Feasibility of completion of cognitive screening tests should not be assumed.  
In the stroke population we studied, most participants needed assistance to 
complete tests and even “short” assessments had substantial rates of non-
completion. 
 
• Where a multi-item cognitive test is only partially compete, the method used to 
account for the missing scores will impact on potential screen positive rates 
and diagnostic properties of the test.  
 
• Clinicians and researchers need to have explicit protocols for dealing with 
partial test completion, We recommend a method that makes greatest use of 
the available data. 
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Objectives:Cognitive screening is recommended in stroke, but test completion may 
be complicated by stroke related impairments.  We described feasibility of 
completion of three commonly used cognitive screening tools and the effect on 
scoring properties when cognitive testing was entirely/partially incomplete. 
Methods:We performed a cross-sectional study, recruiting sequential stroke patient 
admissions from two University Hospital stroke rehabilitation services.  We assessed 
Folstein’s Mini-Mental State Examination (MMSE); Montreal Cognitive Assessment 
(MoCA); Addenbrooke’s Cognitive Examination (ACE-III).  The multidisciplinary team 
gave an independent diagnostic formulation.  We recorded numbers fully/partially 
completing tests, assistance and time required for testing.  We calculated test 
discrimination metrics in relation to clinical assessment using four differing statistical 
approaches to account for incomplete testing.     
Results:We recruited 51 patients.  Direct assistance to complete cognitive tests was 
required for 33 (63%).  At traditional cut-offs, the majority screened “positive” for 
cognitive impairment (ACE-III:98%; MoCA:98%;MMSE:81%).  Comparing against a 
clinical diagnosis, ACE-III and MoCA had excellent sensitivity but poor specificity.  
Partial completion of cognitive tests was common (ACE-III:14/51, MMSE:22/51; 
MoCA:20/51 fully complete), greatest non completion was for test items that required 
copying or drawing.  Adapting analyses to account for these missing data gave 
differing results, MMSE sensitivity ranged from 0.66-0.85 and specificity ranged from 
0.44-0.71 depending on the approach employed. 
Conclusions:For cognitive screening in stroke, even relatively brief tools are 
associated with substantial incompletion.  The way these missing data are 
accounted for in analyses impacts on apparent test properties.  When choosing a 
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cognitive screening tool, feasibility should be considered and approaches to handling 
missing data made explicit.   
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Introduction 
Specialist stroke societies and clinical guidelines recommend routine cognitive 
screening of all stroke survivors (Hachinski et al 2006).  Various approaches to 
screening have been described but there is no consensus on the optimal 
assessment for use in stroke (Lees et al 2012).  Although stroke specific 
assessments are available (Demeyere et al 2015), most centres still use tools 
developed for non-stroke settings: Folstein’s Mini Mental State Examination (MMSE) 
(Folstein et al 1975); the Montreal Cognitive Assessment (MoCA) (Nasreddine et al 
2005); and iterations of the Addenbrooke’s Cognitive Examination (ACE) (Crawford 
et al 2012). 
 
Each of these tools has advantages and limitations.  MMSE has traditionally been 
the favoured assessment for hospital and research work and there is considerable 
experience with this test (Creavin et al 2016).  However, MMSE is perceived to 
provide limited assessment of executive problems (Dong et al 2010) and copyright 
limits its use.  MoCA is recommended for vascular cognitive impairment (Hachinski 
et al 2006), however MoCA thresholds were derived to assess for mild cognitive 
impairment in community dwelling older adults and may need to be revised in stroke 
settings (Davis et al 2015).  The current, third, revision of ACE (ACE-III) provides 
comprehensive assessment but experience is limited particularly in stroke (Hsieh et 
al 2013). None of these tests were specifically designed for use with a stroke 
population  
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Systematic review describing cognitive assessment tools in stroke suggests that 
accuracy of most multi-domain screening assessments is similar and so choice of 
test should be guided by other factors such as feasibility and test burden (Lees et al 
2014a).  Feasibility is a particular concern in stroke, as standard “pencil and paper” 
type assessments may be compromised by clinical issues such as: aphasia; 
concomitant medical illness and physical or sensory impairments.   
 
There is no consensus on how to interpret results when clinical impairments 
preclude test completion (Pendlebury et al 2015).  In some studies, patients unable 
to complete full cognitive testing have been excluded, or test scores have been 
adapted.  The methods used to handle such missing data may impact on the validity 
of results.  There is an emerging literature in diagnostics around incorporating non-
completed results into test accuracy, but the use of “intention to diagnose” has not 
hitherto been described in the context of cognitive assessment in stroke (Scheutz et 
al 2012) 
 
Methods 
Our aims were to describe the feasibility of three cognitive screening tools, ACE-III, 
MMSE and MoCA, in a stroke rehabilitation setting and to explore the effects of 
failed test completion on the interpretation of their results.  Specifically we tested the 
effect of four different approaches to scoring test data when some or all items were 
not completed. 
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We followed conduct and reporting standards for cognitive test accuracy studies 
(STARDdem) (Noel-Storr et al 2014).  The study had approvals from National 
Research Ethics Scotland (14/SS/0042). 
 
Setting: We recruited from two University Hospital stroke rehabilitation units.  Both 
sites operate similar care pathways, with patients first admitted to the acute stroke 
unit and subsequent transfer to the rehabilitation site if patients have persisting 
impairments but are otherwise medically stable. 
 
Population: We included consenting adult patients with confirmed diagnosis of 
stroke.  Where capacity to consent was impaired we approached a relative or carer.  
We recruited participants at a minimum of two weeks post stroke event.  We 
operated few exclusion criteria but did not approach those patients where the clinical 
team felt that any attempt at cognitive assessment was inappropriate.  We assessed 
for concomitant issues of depression and delirium but did not exclude patients based 
on results of these tests.    
 
Screening assessments: Core assessments were ACE-III, MMSE, and MoCA,   
performed by two psychology graduates (RAL, KH) fully trained in use of the scales.  
We used standard cut-points to define “screen positivity” (ACE-III<88/100; 
MMSE<27/30; MoCA<26/30).  We also used alternative cut-offs that may be more 
suited to stroke populations (ACE-III<82; MMSE<24/30; MoCA<22/30) (Lees et al 
2014a).  Tests were administered using pencil and paper and standard assessment 
 
 
8 
 
paperwork with researchers offering verbal instruction in the first instance and further 
assistance as required.  If participants were unable to complete any part of the test 
on first assessment they were approached a second time at least one week later.  
We assessed for delirium using the Confusion Assessment Method (CAM) (Inouye et 
al 1990), and depression using the Patient Health Questionnaire (PHQ) (Spitzer et al 
1999). 
 
Clinical assessment: Our reference standard was multidisciplinary team 
assessment of cognition.  The final formulation was made by an experienced 
consultant in Geriatric Medicine informed by clinical psychology and occupational 
therapy assessments.  The classification of post stroke cognitive impairment was 
based on current recommendations and required multi-domain cognitive problems 
that impact on function (Brainin et al 2015).  Recognising that assessing the 
functional impact of cognition can be difficult while still inpatient, we operationalised 
“clinically significant” impairments as interfering with rehabilitation or discharge.  
Results of research study test scores were not shared with the clinical team as 
standard, although could be disclosed on request.  The researchers performing 
screening assessments and analyses did not have access to the clinical team’s 
diagnostic formulations.  
 
Process: We kept a log of all admissions.  We extracted basic demographic and 
clinical details from patient case notes and recorded details on a standardised 
proforma.  We included details on previous diagnosis of dementia or mood disorder, 
and presence of visual or hearing impairments (which are assessed by the clinical 
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team at time of admission). We described initial (admission to acute stroke unit) 
stroke severity using National Institutes of Health Stroke Scale (NIHSS) (Brott et al 
1989). 
 
Order of test administration and researcher administering the tests alternated 
between patients.  With three tests, there were six different potential orderings of test 
administration; these were changed from patient to patient according to a pre-
specified schedule.  Choice of first test administrator was based on simple coin toss 
and then alternated for sequential patients.  We split the assessments across a 
minimum of two sessions on separate days to reduce patient burden and fatigue.   
 
Outcomes: We recorded numbers of patients admitted to each stroke rehabilitation 
unit, numbers eligible for the study, and numbers that completed each test (total test 
and individual components).  Time taken for test administration was recorded using a 
stopwatch.  We recorded impairments that complicated test completion and whether 
the researcher had to provide direct assistance.  Where a patient required some 
assistance but was still able to complete the test this was recorded as test 
completed.   
 
Analyses: We compared proportions completing each test, proportions “screen 
positive” on each test at the various cut-offs, and time taken to administer tests using 
chi-square and ANOVA tests.     
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We described test accuracy of each test against the multidisciplinary teams’ clinical 
reference standard diagnosis using four differing approaches that account for 
partially or entirely incomplete tests.(Table 1) 
 
Results 
 
From August 2014 to February 2015 inclusive, 86 patients were admitted to the 
stroke rehabilitation units, 75 (87%) were eligible for our study and we recruited n=51 
(68% of eligible).(Figure 1).  Median age of included patients was 74 years (IQR:67-
84); 28 (55%) were female and median NIHSS was 9 (IQR:6-13).  Eighteen patients 
(35%) were classified as total anterior circulation strokes (TACS) and 39 (76%) were 
ischaemic.  Median time since stroke was 36 days (IQR:20-55).  Eight (16%) patients 
had delirium by CAM criteria at time of testing; four (8%) had a recorded diagnosis of 
dementia prior to their stroke.  Six (12%) had pre-stroke depression, and median 
score on PHQ was 5 (IQR:3-10, range:0-24). Ten patients (20%) had pre-stroke 
hearing or visual impairments. 
 
There was a difference in time to complete individual cognitive tests (p<0.001), with 
median time to complete ACE-III:18 minutes (IQR:15-22, range:10-35); MMSE:5 
minutes (IQR:5-6, range:3-20); and MoCA:9.5 minutes (IQR:7-11, range:6-20) (Table 
2).  Of included patients, 33 (65%) had impairments that complicated assessments and 
required direct assistance from researchers.  We recorded a variety of impairments, the 
most common were motor weakness (for example patient unable to write for “pen and paper” 
type assessments) and communication problems (usually due to aphasia).(Figure 1).  
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Partial completion of cognitive tests was common (ACE-III:14/51, MMSE:22/51; 
MoCA:20/51 fully complete).  Examining specific cognitive test domains, in those 
tests where at least one item was completed, the greatest non completion rate was 
for test items that required copying or drawing (intersecting pentagons from MMSE 
not completed in 9 tests; visuospatial/executive items from MoCA not completed in 
11 tests; and visuospatial items from ACE-III not completed in 11 tests).   
 
We described the comparative accuracy of the various tests.  We compared against 
a gold standard of multidisciplinary team assessment, but would emphasise that the 
test used are not suitable for making a diagnosis of dementia on their own.  Using 
“traditional” cut-offs and analyses, the majority of patients screened with ACE-III, 
MMSE and MoCA had results consistent with cognitive impairment (“screen positive” 
in 98%,81% and 98% respectively).  Altering the cut-offs to those suggested as more 
appropriate for stroke (Lees et al 2014a) resulted in fewer “screen positives”.(Table 
2) 
 
Final MDT criterion diagnostic formulation identified post stroke cognitive impairment 
in 27 patients (53%).  Assessing screening tests against the MDT diagnostic 
formulation, ACE-III and MoCA were sensitive but not specific.  Test accuracy values 
varied depending on the approach used for handling missing data.(Table 2) 
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Discussion  
In this study we examined the feasibility of using short cognitive screening tests in a 
stroke rehabilitation population.  Even with dedicated researchers and approvals to 
allow proxy consent we were still only able to recruit around two thirds of eligible 
stroke patients into this study, and of those recruited another two thirds had 
impairments that impacted on completion of cognitive screening tests.  These 
impairments were a mix of stroke related issues and pre-existing problems.  Time 
taken to complete the cognitive tests was similar to that quoted for non-stroke 
settings, but many subjects needed assistance to complete the tests (Woodford and 
George 2007).  In this study we had dedicated and trained research staff, and we 
recognise that feasibility of using these tests may be less still if administered by busy 
clinical staff. 
 
We used our dataset to investigate the implications of four different approaches to 
handling missing cognitive test data.  Depending on the approach, the prevalence of 
“screen positives” and the properties of the tests could vary substantially.  This was 
particularly evident for MMSE as the other tools had extreme values for 
sensitivity/specificity.   
 
There are many multi-domain cognitive screening tools available (Lees et al 2012). 
We choose those tests that are most popular in stroke care in the UK.  The ideal 
would have been to compare more than three tests, but we were mindful of patient 
test burden, particularly in a study designed to assess feasibility.  Shorter cognitive 
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screens, such as the four question abbreviated mental test are available (Schofield 
et al 2010) and are popular in time limited situations such as acute stroke (Lees et al 
2013).  The purpose of these very brief screens is more around early triage than 
informing an assessment of cognitive impairments.   
 
We chose a reference standard that we felt was best suited to the rehabilitation 
setting and which recognises the difficulties of making a clinical dementia diagnosis 
in the early to medium term following stroke.  Our reference standard was 
multidisciplinary assessment by an experienced team.  This remains the ideal 
assessment modality and was possible in this rehabilitation unit based study.  
Unfortunately the increasingly fast pace of acute stroke care with a focus on early 
discharge from secondary care precludes this form of multidisciplinary assessment 
for many people affected by stroke.  This is particularly true for those with minor 
physical impairments, who tend to be managed as outpatients or with short hospital 
stays, but who often have persisting cognitive issues (Pendlebury et al 2011). 
 
The strengths of our study include a “real world” approach, attempting to include all 
patients where the clinical team felt an attempt at assessment was indicated.  By 
gaining approvals to include patients lacking capacity to consent, we had access to a 
population that is not biased by exclusion of those with potential major cognitive 
issues.    
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There are limitations in our approach.  We chose to assess a patient population of 
stroke survivors requiring inpatient rehabilitation.  Although this limits external 
generalisability to other stroke groups, this group is suited to a study of feasibility.  If 
cognitive testing strategies are feasible in a population with substantial impairments, 
they should be feasible in any group of stroke survivors.  We required patients or 
their proxy to provide consent to testing and this may have biased the sample, 
particularly around feasibility.  The sample size was modest.  We did not pre-specify 
a sample size since one of the metrics of interest was feasibility of recruitment to a 
cognitive study over a fixed time period.   To limit test burden we spread assessment 
over at least two sessions.  This may have impacted on the between study 
variability, particularly in the context of delirium (16% in this study). 
 
Our study adds to the limited, but growing, literature on feasibility of cognitive testing 
in stroke (Lees et al 2014b).  Completion rates of 68%-80% (Cumming et al 2011) for 
MoCA have been reported in acute stroke (Horstmann et al 2014).  The differences 
may relate to differing case-mix.  Where MoCA completion rates were assessed as 
part of an acute rehabilitation study programme, overall completion rates were 
reasonable (75%) but rates were low in those with more severe stroke at baseline 
(67%) (Pasi et al 2013).    When testing is either partially or entirely incomplete, it is 
common to exclude these data.  This approach can lead to biased results (Wall et al 
2015) 
 
Our study highlights a number of important evidence gaps in the application and 
interpretation of cognitive screening tests in stroke.  Examples of fundamental issues 
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that need further research include, how early after stroke should cognitive screening 
be performed; which tests should be used, and is a universal screening policy 
preferable to modifying the screening test used in relation to patient impairments.  
 
There is no ideal cognitive screening tool, and choice of assessment instrument 
should be guided by the purpose of the test, feasibility and acceptability.  It is 
interesting that the MMSE, a tool which is becoming less popular in stroke due to 
perceived lack of utility (ceiling effects, focus on memory), was quickest to complete; 
had highest Youden index and had the most balanced trade-off between sensitivity 
and specificity at chosen scoring threshold.  MoCA and ACE-III, tests developed 
primarily for assessment of mild cognitive impairment, were sensitive but had poor 
specificity (Table 2). 
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Conclusions (Recommendations for clinical practice and research) 
Contemporary practice in stroke medicine pharmacotherapy is based on a robust 
evidence of randomised controlled trials and meta-analyses (McArthur et al 
2011,Brainin et al 2015).  We have highlighted potential limitations in contemporary 
guidance around neuropsychological assessment.  Our findings of potential poor 
feasibility and differential results dependant on analysis method, have implications 
for practice, policy and research.    
 
Our results need to be considered in the context of health-care policy that suggests 
“universal” cognitive screening.  There are problems with using cognitive screening 
tools developed for use with community dwelling older adults in a stroke population 
with high prevalence of physical, mood and cognitive problems.  In choosing a 
cognitive assessment, feasibility needs to be considered along with classical test 
properties such as accuracy.   
 
In our cohort, most patients required assistance to complete the screening tests and 
even with these relatively short screening instruments there was still substantial non 
completion.   
 
Screening stroke inpatients with MoCA or ACE-III at traditional diagnostic cut-offs 
may not have particular clinical utility as almost all patients will screen positive.  If the 
purpose of testing is to define a level of impairment that impacts on rehabilitation 
then thresholds should be adjusted. 
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We would not propose abandoning brief cognitive screens in stroke settings, but it is 
important that users of these tests appreciate the clinical “meaning” of the test 
results.  We propose a stepped approach that uses very brief tests and clinical 
assessment to triage into categories of: unlikely to have important cognitive 
impairments but keep under review; may have important cognitive issues and needs 
further assessment; severe stroke, likely to have cognitive issues and unlikely to be 
able to complete testing therefore modify approach accordingly.  The multi-domain 
screening tools assessed in this paper could be reserved for those in the middle 
category. 
 
As cognitive testing becomes a standard part of acute stroke care and assessment, 
as recommended in various guidelines and in keeping with a general move in 
secondary care to improve early diagnosis of cognitive issues,  we would encourage 
further research around feasibility and acceptability metrics as well as traditional test 
accuracy measures.  Feasibility of testing cognitive impairment in different patient 
groups should also be encouraged. 
 
In clinical practice, audit, and in research studies that use cognitive assessments 
there needs to be a priori planning for how missing cognitive data are handled.  
Whatever approach is chosen, this needs to be made explicit in protocols and study 
related publications.  To allow comparisons between studies it is important that the 
research community is consistent in the approach used. 
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Our data do not suggest that any of the proposed approaches to handling missing 
cognitive test data is superior in terms of correct classification.  We would 
recommend the approach to cognitive test scoring that makes greatest use of 
available data (i.e. where all incomplete test items are scored as “zero”, described as 
approach four in this paper, the most inclusive approach).  Further work exploring 
the implications of various approaches to missing data is warranted and data from 
existing trial registries could be used in this regard.   
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Figure 1 Recruitment Flow Chart 
 
 
Flow chart detailing numbers of patients admitted to two stroke rehabilitation and 
numbers completing cognitive tests.  
* Some participants had more than one impairment affecting assessment 
** Some patients who required assistance were able to complete tests; some 
patients not completing tests did not require direct assessor assistance 
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Table 1.Four Approaches To Scoring Tests When Data Are Incomplete  
The figure gives a theoretical example of how differing approaches to handling 
missing data can impact on results. We use the Montreal Cognitive Assessment 
(MoCA) and present test score for each of the individual test domains.  Assuming 
five patients with differing impairments were administered the MoCA, scores for 
individual items are presented (white boxes) in the columns labelled “Patient 1-4”. 
In the grey fill boxes we present the total MoCA score, sum of individual item scores, 
modified by the approach to missing data.  We include examples of entirely 
incomplete (Patient 3) and partially incomplete (Patients 4 and 5) test data.  These 
scores are chosen to illustrate the potential effect of differing approaches to scoring 
missing test data on proportion of patients tested who are “screening test positive”.       
 
MoCA domain Patient 1 Patient 2 Patient 3 Patient 4 Patient 5  
Visuospatial/executive 
(maximum score 5)  4 2 
unable to 
complete 
unable to 
complete 2 
Naming  
(maximum score 3) 3 3 
unable to 
complete 3 
unable to 
complete 
Attention 
(maximum score 6) 6 4 
unable to 
complete 4 4 
Language 
(maximum score 3) 2 2 
unable to 
complete 2 
unable to 
complete 
Abstraction 
(maximum score 2) 2 2 
unable to 
complete 2 2 
Recall 
(maximum score 5) 4 3 
unable to 
complete 5 3 
Orientation 
(maximum score 6) 6 3 
unable to 
complete 5 3 
 Proportion “test 
positive” 
Total score  
(Approach 1) 27/30 19/30 
not 
included 22/30 14/30 
3/4 (75%) 
Total score  
(Approach 2) 27/30 19/30 
not 
included 22/25 14/22 
2/4 (50%) 
Total score  
(Approach 3) 27/30 19/30 
not 
included 
not 
included 
not 
included 
1/2 (50%) 
Total score  
(Approach 4) 27/30 19/30 00/30 22/30 14/30 
4/5 (80%) 
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Approach 1: Excluding those patients whose testing was entirely incomplete, and 
assigning a score of zero to partially completed items. 
Approach 2: Excluding those patients whose testing was entirely incomplete, and 
for patients whose testing was partially incomplete adapting the total test score and 
threshold by excluding non-completed items from the total score.   
Approach 3: Excluding all patients with either entirely or partially incomplete testing, 
i.e. only including those patients with fully completed tests (the most restrictive 
approach). 
Approach 4: Including all patients but assigning a minimum value (usually zero) to 
any incomplete items, hence giving a total score of 0 where testing was entirely 
incomplete (the most inclusive approach).  
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Table 2.Accuracy of Cognitive Screening Tools 
Measures of discrimination (with 95% confidence intervals) of cognitive screening 
tools, using adapted thresholds suggested for stroke, against a clinical reference of 
cognitive impairment, using four differing approaches to account for entirely or 
partially incomplete cognitive test data. 
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  Approach 1 Approach 2 Approach 3 Approach 4 
A
C
E-
III
 <
 8
2/
10
0 
CCR 0.49 0.47 0.67 0.54 
Youden index -0.08 -0.09 0.04 -0.05 
Sens 0.87 
(0.66-0.97) 
0.81 
(0.59-0.95) 
0.93 
(0.66-1.00) 
0.90 
(0.73-0.98) 
Spec 0.05 
(0.01-0.25) 
0.10 
(0.01-0.31) 
0.11 
(0.01-0.35) 
0.05 
(0.01-0.22) 
PPV 0.52 
(0.35-0.68) 
0.48 
(0.32-0.66) 
0.45 
(0.26-0.64) 
0.56 
(0.41-0.71) 
NPV 0.25 
(0.01-0.81) 
0.33 
(0.04-0.78) 
0.67 
(0.09-0.99) 
0.25 
(0.01-0.81) 
 
M
M
SE
 <
 2
4/
30
 
CCR 0.64 0.69 0.67 0.64 
Youden index 0.30 0.37 0.34 0.29 
Sens 0.78 
(0.52-0.94) 
0.66 
(0.40-0.86) 
0.71 
(0.42-0.92) 
0.85 
(0.65-0.96) 
Spec 0.52 
(0.30-0.74) 
0.71 
(0.48-0.89) 
0.63 
(0.35-0.85) 
0.44 
(0.24-0.65) 
PPV 0.58 
(0.37-0.78) 
0.67 
(0.41-0.87) 
0.63 
(0.35-0.85) 
0.61 
(0.43-0.77) 
NPV 0.73 
(0.45-0.92) 
0.71 
(0.48-0.89) 
0.71 
(0.42-0.92) 
0.73 
(0.45-0.92) 
 
M
oC
A
 <
 2
2/
30
 
CCR 0.47 0.51 0.55 0.53 
Youden index 0.05 0.15 0.14 0.04 
Sens 1.00 
(0.80-1.00) 
1.00 
(0.80-1.00) 
1.00 
(0.75-1.00) 
1.00 
(0.87-1.00) 
Spec 0.05 
(0.01-0.24) 
0.15 
(0.03-0.37) 
0.14 
(0.01-0.43) 
0.04 
(0.01-0.20) 
PPV 0.46 
(0.29-0.63) 
0.47 
(0.27-0.67) 
0.52 
(0.31-0.72) 
0.52 
(0.37-0.66) 
NPV 1.00 
(0.03-1.00) 
1.00 
(0.29-1.00) 
1.00 
(0.15-1.00) 
1.00 
(0.03-1.00) 
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See Table 1 for further details on definition of each approach  
CCR=Correct Classification Rate 
PPV/NPV=positive / negative predictive values 
